Michael Brines oversees Scientific Programming and is a Professor at the Feinstein Institutes for Medical Research. He is dedicated to translating scientific breakthroughs into therapies that significantly enhance patient well-being.
With a PhD in Neurobiology and Behavior (The Rockefeller University) and MD (Yale), complemented by extensive training in Internal Medicine, Endocrinology, and Clinical Investigation, he has accumulated over 40 years of experience in biomedical research focused on tissue injury and therapeutic innovation.
Formerly a Professor of Internal Medicine at Yale University and co-founder of Warren Pharmaceuticals and Araim Pharmaceuticals, his work has led to over 200 scientific publications and numerous patents worldwide, underscoring significant contributions to the field.
He identified the protective role of erythropoietin in the body’s response to injury, discovering a novel receptor that mediates its beneficial effects and deigned novel peptide activators as potential therapeutics.
He can be reached at: mbrines@northwell.edu.